Biosimilars Battle: Celltrion’s Remsima Takes On J&J’s Remicade In Korea
This article was originally published in PharmAsia News
Executive Summary
Although still early after launch, Celltrion is battling J&J in the Korean market with a biosimilar of Remicade. If the war of words is any indication, things are just starting to heat up.
You may also be interested in...
J&J Taking The Long View With Its Therapeutic Franchises
The Big Pharma has only recently entered the diabetes drug market, but has plans to make a significant impact on how the disease is treated. During a meeting with analysts, J&J highlighted the deals it’s made and the multiple indications it will pursue within the metabolic space.
Biosimilar Remicade Will Pit Rising Cost Pressures Against Prescriber Caution
If approved in Europe this year, as expected, Celltrion/Hospira’s biosimilar infliximab will provide a compelling test of whether and how quickly budgetary pressures can override physician caution. It will also set the stage for the $70 billion worth of copycat antibodies in development.
Early-Stage Idiopathic Pulmonary Fibrosis (IPF) Candidates Race to Phase III
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.